Niagen
Niagen is a pharmaceutical drug with 9 clinical trials. Currently 2 active trials ongoing. Historical success rate of 85.7%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
0
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
85.7%
6 of 7 finished
14.3%
1 ended early
2
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Nicotinamide Riboside for Diabetic Neuropathy
Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment
Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment
Clinical Trials (9)
Nicotinamide Riboside for Diabetic Neuropathy
Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment
Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment
Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
NR Supplementation and Exercise
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9